Background: Temporary mechanical circulatory support (MCS) offers a valuable option for treatment of refractory heart failure. We present our experience with selected MCS devices in cardiogenic shock of different etiologies.
Introduction
Cardiogenic shock can present as isolated right, left or combined biventricular heart failure (HF), leading to lung edema and organ malperfusion, factors that have a direct impact on survival. In contemporary registries, decompensated dilated cardiomyopathy (DCMP) and ischemic cardiomyopathy (ICMP) together with acute myocardial infarction (AMI) are the main reasons for cardiogenic shock (1, 2) . Currently available temporary mechanical circulatory support (MCS) devices are considered options for treatment of cardiogenic shock (3, 4) and provide a large variety of short-term support strategies; however, none of the contemporary devices has shown a significant outcome improvement and no randomized control trial of commercially available devices has be conducted so far (5) .
Extracorporeal life support (ECLS) is the most common temporary MCS device, due to its reasonable cost and availability in every cardiothoracic surgery department as well as in many large cardiology departments with frequent acute percutaneous coronary intervention (PCI) procedures. Veno-arterial cannulation provides both oxygenation and circulation support. The peripheral placement, the option to install the support at the bedside and its suitability for use during cardiopulmonary bypass as an alternative to the heart-lung-machine makes ECLS an attractive option for circulatory support (5, 6) .
A major disadvantage of ECLS is the lack of ventricular unloading. Furthermore, the outflow in the aorta creates an extremely high afterload, increasing the oxygen demand and wall tension of the myocardium, and thereby coronary perfusion worsens. Moreover, blood stasis in the left ventricle causes pulmonary hypertension, leading to interstitial lung edema (5,7).
There are some options to improve ventricular unloading, starting with inotropic support and escalating to intra-aortic balloon pump (IABP) (8) . However, this concept has failed to provide survival benefit in AMI patients in the IABP Shock 2 trial (9,10).
Therefore, a potential therapy of choice could be implantation of the Impella (AbioMed, Danvers, MA, USA) device (5, 7, 11) . Impella is a family of miniature rotatory pumps that can provide flow of 2.5 to 5 L/min, depending on the size of the vessel and the support needed. The Impella 5.0 pump, which is that most frequently used in our department, is placed through an arterial cut-down. With flow rates of up to 5 L/min it can offer full support. Compared to ECLS, Impella fully unloads the left ventricle, preventing pulmonary edema and reducing the myocardial oxygen consumption. Moreover, Impella therapy requires much less anticoagulation than ECLS. The characteristics of modern left ventricular MCS devices are presented in Table 1 [adapted from (3) (4) (5) (6) ].
Most of the long-term implantable MCS devices were primarily designed for left ventricular support; nevertheless, proper right heart function plays a key role for the circulation. Up to 10-15% of patients develop acute right HF (RHF) after left ventricular assist device (LVAD) implantation, with subsequent need for biventricular support (12) . A small group of patients may develop isolated RHF, mostly after acute myocardial infarction due to occlusion of the right coronary artery. Nowadays, four devices can be used for the therapy of RHF: ECLS, Tandem Heart (Cardiac Assist Inc., Pittsburgh, PA, USA), Impella RP (AbioMed) and CentriMag (Thoratec, Pleasanton, CA, USA) (5) (see Table 2 ) [adapted from (3) (4) (5) ].
At the German Heart Center Berlin (Deutsches Herzzentrum Berlin, DHZB) the CentriMag centrifugal blood pump is considered the most advantageous MCS device for isolated right ventricular support. The magnetically levitated impeller minimizes the potential friction and shear forces on blood cells, preventing hemolysis. The maximal speed of 5,500 rpm allows blood flow of up to 9.9 L/min to be generated. The impeller is built into a transparent plastic corpus, allowing visual evaluation of the flow. CentriMag provides a versatile mechanical support for right, left or biventricular HF; moreover, a membrane oxygenator can be added, providing pulmonary support (13) . It is the most biocompatible system and is approved for up to four-week use (14) , although it can be used successfully for a much longer time (15) . CentriMag is recommended as a baseline biocompatibility control pump for future MCS devices (14) .
Cannulation for the outflow cannula as a right ventricular assist device (RVAD) may be performed directly in the pulmonary artery, or through the wall of the right ventricle and pulmonary valve, or using a vascular graft attached to the pulmonary artery. Further, the long Bio-Medicus ® femoral venous cannula (Medtronic Inc., Mounds View, MN, USA) may be placed percutaneously through the right internal jugular vein into the pulmonary artery under fluoroscopic or echocardiographic guidance (6, 16) . The inflow cannula should drain the right atrium, mostly using peripheral venous access. Totally percutaneous access is also possible. See Table 2 for the access sites for the different devices.
Beside these pathophysiological considerations, concrete data of short term MCS devices in the setting of acute right and left HF remains scarce. The aim of this study is to further evaluate outcome parameters as well as potential advantages and disadvantages of short term MCS therapy.
Methods
We performed a single center retrospective analysis of a contemporary cohort of patients with cardiogenic shock, supported in our institution with Impella for short-term left ventricular circulatory support (01/2016 to 07/2018) and with CentriMag for short-term right ventricular support (01/2015 to 07/2018).
Results

Impella LVAD
The demographics of the patients are shown in Table 3 .
In four (11%) cases, left axillary artery access was used and in 28 (76%) cases, the right axillary artery was accessed; in two (5%) cases, the right femoral artery was punctured and in two cases, the left femoral artery was used.
In one (3%) patient, due to high-grade stenosis of the axillary arteries and narrow femoral arteries, the Impella 5.0 device was inserted directly into the ascending aorta via a median sternotomy. In three cases, implantation was not successful due to a small axillary artery and in two, an Impella CP was inserted. In one case the Impella 2.5 was used.
Nine (24%) patients were on ECLS during Impella implantation. In these cases, Impella was used as a vent. Of these ECLS patients, three had ECLS explanted and Impella continued to work as an LVAD. In 28 (76%) cases, Impella was used primarily as an LVAD. From the total 37 patients, nine were bridged to long-term VAD after mean support duration of 13.9 days (2-69 days), seven (19%) were weaned after 16.6 days (5-25 days) and 20 died during support (mean 6.54 days; range, 19 h to 43 days). Nine (24%) patients received an IABP implantation before Impella; in eight (22%) cases severe hemolysis prompted a pump explantation. The patient outcomes are presented in Figure 1 . The overall mortality on device was 54% ( Table 4) .
CentriMag RVAD
The demographics of the CentriMag group are shown in Table 5 and the patients' outcomes are presented in Figure 1 . In 62 (90%) cases, direct access to the pulmonary artery (39 cases through vascular graft) was chosen for blood return and in seven (10%), percutaneous cannulation through the jugular vein (6, 16) . In 48 (70%) cases, peripheral cannulation for venous drainage was employed and in 21, the RA was directly cannulated.
Of 69 patients, ten (14.5%) were transited to long-term RVAD after a mean of 61.9 days, 20 (29%) were Thirty-nine (57%) patients died on CentriMag support ( Table 4) .
Discussion
Despite the latest improvements in short-term MCS devices and the rising number of implantations, the therapy of acute refractory HF remains challenging, with high mortality rates.
The etiology of HF plays a key role for the MCS therapy choice. In our study we describe two different patient groups with left and with right ventricular failure, leading to cardiogenic shock. In patients suffering from cardiogenic shock caused predominantly by left ventricular failure, the Impella LVAD is a valuable option as a bridge to decision or recovery. However, "crash and burn" patients (Intermacs profile 1) and patients under cardiopulmonary resuscitation (CPR) or with evident multi-organ failure, especially with lung failure, should be treated by ECLS. Full cardiopulmonary support and rapid installation play a crucial role in these patients (17) . Between 01/2012 and 01/2018 in our institution 714 patients were supported with ECLS. Patients who underwent long-term LVAD implantation after hemodynamic stabilization on ECLS present 62% 30-day survival and 43% one-year survival, which is acceptable in the setting of severe cardiogenic shock (18) .
The successful use of Impella devices during high-risk PCI and reduced mortality rates in at least smaller trials made it an attractive therapy strategy in cardiology (19, 20) . However, its preventive use completely differs from the therapy of patients in manifest cardiogenic shock. The majority of patients in previous studies developed cardiogenic shock after AMI or postcardiotomy. Survival in this setting was around 50% (11, 21) . Early implantation in cardiogenic shock is crucial and has to be aimed for (22); on the other hand, futility has to be avoided. Therefore, timely referral and adequate evaluation are cornerstone.
Comparison of survival rates is difficult, since etiology and exclusion criteria as prescribed above differ, but compared to previous studies, survival tends to be higher if patients are supported with the Impella device (23, 24) . Some factors such as resuscitation before or during Impella therapy or pathological venous blood pH on admission may be considered as low survival predictors ( Table 6 ). In cases of postcardiotomy cardiogenic shock, the threshold for the decision should be moved toward earlier implantation to avoid multi-organ failure (17) . However, there is no evidence that a more aggressive approach would improve the outcome. Adverse events under support occurred in 43% of patients with Impella support and are therefore comparable to the rate with ECLS therapy (24) ( Table 7) .
Nevertheless, second-line Impella 5.0 implantation can be successfully performed in patients showing no myocardial recovery on prolonged ECLS support or suffering from complications of ECLS therapy (25) .
A great potential of Impella use is the step-up approach in patients already supported by ECLS. This approach was used in our cohort. In nine patients who underwent Impella implantation in the setting of LV distention only one case of bleeding, infection and stroke (respectively) was diagnosed (this complications are associated with Impella therapy only). A multicenter study by Pappalardo et al. demonstrated a significant improvement of outcomes in patients who underwent simultaneous ECLS and Impella (so called ECMELLA) therapy, compared with VA-ECLS use only (26, 27) . The recent retrospective single center study by Patel et al. also showed a reduction in mortality rates in ECMELLA patients. Decreasing use of inotropic support and a lower complication rate were also reported (6) .
In June 2018, Pappalardo et al. reported biventricular circulatory support with Impella CP and Impella RP in a patient with acute cardiogenic shock, which developed after ischemic stroke, complicated with pulmonary hypertension (28) . The simultaneous use of two Impella devices in a setting of biventricular support could be a promising alternative compared to more invasive methods; however, the difficulties in placement and the lack of experience with Impella RP, especially in a prolonged therapy concept, remain a limiting factor. Therefore, we consider CentriMag right heart support as the current option of choice. Among our patients, maximal right ventricular support with CentriMag of 118 days was demonstrated. The longest CentriMag therapy of 304 days was described by Griffith et al. in 2012 (15) . The mortality of patients supported with CentriMag RVAD is expected to be high, since many patients who develop RHF after LVAD implantation have previously had chronic RV failure, are predominantly in Intermacs profile 1 or 2 or have been previously supported with ECLS. In a meta-analysis by Borisenko et al., 30-day survival of 61% (46-75%) was demonstrated for this group of patients (29) . Simultaneous use of long-term LVAD with short-term RVAD in the setting of biventricular support might be considered to be more advantageous than primary biventricular assist device (BiVAD) implantation because of the ability to wean a relevant proportion of patients after right heart recovery and therefore potentially fewer long-term complications. Nowadays there is no continuous flow longterm ventricular assist device (cfVAD) designed for right ventricular support available. Therefore, LVADs such as HeartMate 3 and HeartWare have to be implanted (30) . In a work by Eulert Grehn from our center, patients who underwent primary cfVAD implantation were compared with those who received subsequent implantation after short-term right ventricular support, including with the CentriMag pump. The primary cfVAD implantation has shown no significant increase in survival compared with the subsequent implantation: 72.7% vs. 71.4% in 30-day survival (31) . Prospective and randomized clinical trials comparing the outcomes of primary and subsequent cfVAD implantation in the setting of biventricular heart support are needed; however, short-term RVAD therapy is a valuable option for a selected group of patients in post-LVAD RHF. In this setting CentriMag can be used as an approved therapy.
Limitations
The present article reports a single-center experience in a small cohort of consecutive patients; results should be confirmed in larger multicenter randomized studies.
Conclusions
Impella for left ventricular support employed in cardiac surgery departments is associated with elevated mortality compared to preventive use during high risk PCI. However, the vast majority of our patients are in profound cardiogenic shock prior to the surgery and, in this setting, the Impella 5.0 implantation can provide sufficient circulatory support with acceptable complication rates.
The CentriMag as a temporary RVAD in the setting of post-LVAD right ventricular failure provides a valuable option if prolonged support is needed and stimulates right heart recovery, which might allow patients to be weaned from the device.
Future studies should evaluate criteria for RV recovery on temporary RVAD. A prospective randomized study comparing different types of temporary MCS in cardiogenic shock would be helpful in improving our treatment of these high-risk patients.
